公开(公告)号：US20170114032A1

公开(公告)日：2017-04-27

申请号：US15314938

申请日：2015-07-16

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Changchung Cheng ,  Yingjun ZHANG ,  Bing LIU ,  Bohua LONG ,  Yu CHEN ,  Zhixin CHENG

IPC: C07D261/14 ,  A61K31/5377 ,  C07D487/04 ,  C07D491/107 ,  A61K31/422 ,  C07D491/056 ,  A61K31/496 ,  A61K31/454 ,  C07D413/12 ,  C07D491/08 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/541 ,  C07D471/04 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/437 ,  C07D513/04 ,  C07D513/14 ,  C07D519/00 ,  A61K45/06

CPC classification number: C07D261/14 ,  A61K31/422 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/056 ,  C07D491/08 ,  C07D491/107 ,  C07D513/04 ,  C07D513/14 ,  C07D519/00 ,  A61K2300/00

Abstract: Provided herein are novel substituted urea derivatives, and pharmaceutical compositions thereof. Also provided herein are uses of the compounds or pharmaceutical compositions thereof for preventing, managing, treating or lessening a proliferative disease, and modulating the activity of protein kinase.

公开(公告)号：US20230121086A1

公开(公告)日：2023-04-20

申请号：US17790908

申请日：2020-12-31

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Bing LIU ,  Yingjun ZHANG ,  Wei PAN ,  Feng WANG ,  Xuke LI ,  Wei HE ,  Jiuzhong HUANG

IPC: A61K31/402 ,  A61K45/06 ,  A61P17/06 ,  A61P37/06 ,  C07D403/12 ,  C07D207/12 ,  C07D401/12 ,  C07D401/14 ,  C07D417/12 ,  C07D403/04 ,  C07D405/12 ,  C07D207/09 ,  C07D211/60 ,  C07D401/04 ,  C07D211/42 ,  C07D211/34 ,  C07D211/22 ,  C07D241/04 ,  C07D295/155 ,  C07D205/04 ,  C07D277/34 ,  C07D231/56 ,  C07D215/06 ,  C07D217/04 ,  C07C317/50 ,  C07D305/08 ,  C07F7/08 ,  A61K31/501 ,  A61K31/506 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/444 ,  A61K31/495 ,  A61K31/397 ,  A61K31/426 ,  A61K31/416 ,  A61K31/47 ,  A61K31/472 ,  A61K31/277 ,  A61K31/337 ,  A61K31/695

Abstract: A RORγt inhibitor as well as a preparation method thereof and uses thereof, and a pharmaceutical composition including the compound, a method for preparing the pharmaceutical composition, and use of the compound or the pharmaceutical composition in the treatment or prevention of RORγt-mediated cancer, inflammation, or autoimmune diseases in mammals, especially humans.

公开(公告)号：US20230067159A1

公开(公告)日：2023-03-02

申请号：US17789956

申请日：2020-12-31

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Yingjun ZHANG ,  Bing LIU ,  Wei PAN ,  Feng WANG ,  Wei HE

IPC: C07D207/06 ,  C07D405/12 ,  C07D413/06 ,  C07D401/04 ,  C07D403/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/10

Abstract: An RORγt inhibitor, a preparation method thereof and uses thereof. The invention also relates to a pharmaceutical composition of the compound, a method for preparing the pharmaceutical composition, and use of the compound or the pharmaceutical composition in treating or preventing cancer, inflammation, or autoimmune diseases mediated by RORγt in mammals.

公开(公告)号：US20180298019A1

公开(公告)日：2018-10-18

申请号：US15769065

申请日：2016-10-18

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Bing LIU ,  Weihong ZHANG ,  Yingjun ZHANG

IPC: C07D491/056 ,  A61P35/04

CPC classification number: C07D491/056 ,  A61K31/337 ,  A61K31/427 ,  A61K31/436 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/573 ,  A61K31/7072 ,  A61K45/06 ,  A61K2300/00 ,  A61P35/04

Abstract: The invention relates to a salt, a hydrate or a crystalline form of an EGFR inhibitor, and use thereof. Specifically it relates to 4-[(3-chloro-4-fluorophenyl) amino]-7-methoxy-6-[3-[(1R,6S)-2,5-dioxa-8-azabicyclo [4.3.0] nonan-8-yl] propoxy]quinazoline dimethanesulfonate, hydrate and a crystalline form thereof; the invention also relates to a preparation method of the crystalline form disclosed herein, a pharmaceutical composition containing the crystalline form, and uses thereof for treating proliferative disorders.

公开(公告)号：US20170267634A1

公开(公告)日：2017-09-21

申请号：US15504018

申请日：2015-09-11

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Yingjun ZHANG ,  Tianzhu YU ,  Bing LIU ,  Xiangyu ZHANG ,  Shiguo ZHANG ,  Changchung CHENG ,  Jiancun ZHANG

IPC: C07D209/14 ,  A61K31/454 ,  C07D401/14 ,  A61K31/4709 ,  A61K45/06 ,  C07D401/12 ,  C07D471/04 ,  A61K31/4375 ,  C07D403/12 ,  A61K31/498 ,  C07D401/04 ,  A61K31/405

CPC classification number: C07D209/14 ,  A61K31/405 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/498 ,  A61K45/06 ,  C07B2200/13 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04

Abstract: The compounds of Formula (I) which can be used as CRTH2 receptor antagonists are provided. The compounds of Formula (I) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin D2 (PGD2) at the CRTH2 receptor.

公开(公告)号：US20160039838A1

公开(公告)日：2016-02-11

申请号：US14774702

申请日：2014-04-28

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Yingjun ZHANG ,  Bing LIU ,  Jinlei LIU ,  Jiancun ZHANG ,  Changchung CHENG

IPC: C07D491/056 ,  C07D413/12 ,  A61K31/553 ,  C07D417/12 ,  A61K31/5415 ,  C07D498/04 ,  A61K31/5383 ,  A61K31/538 ,  C07D491/048 ,  C07D495/04 ,  C07D497/04 ,  C07D401/12 ,  C07D403/12 ,  C07D491/044 ,  C07D519/00 ,  A61K31/5377 ,  A61K33/24 ,  A61K31/7008 ,  A61K39/395 ,  A61K38/21 ,  A61K31/573 ,  A61K38/12 ,  A61K31/282 ,  A61K31/704 ,  A61K31/4545 ,  A61K31/337 ,  A61K31/517

CPC classification number: C07D491/056 ,  A61K31/196 ,  A61K31/198 ,  A61K31/255 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4545 ,  A61K31/475 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5415 ,  A61K31/553 ,  A61K31/573 ,  A61K31/675 ,  A61K31/7008 ,  A61K31/704 ,  A61K33/24 ,  A61K38/12 ,  A61K38/212 ,  A61K39/39558 ,  A61K2039/505 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D491/044 ,  C07D491/048 ,  C07D495/04 ,  C07D497/04 ,  C07D498/04 ,  C07D519/00 ,  A61K2300/00

Abstract: Provided herein are aminoquinazoline compounds, salts and uses thereof. The compounds have Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Also provided herein are pharmaceutical compositions containing the compounds disclosed herein, and uses of the compounds or the compositions for preventing, managing, treating or lessening the severity of a proliferative disorder in a patient and for modulating the protein tyrosine kinase activity.

Abstract translation: 本文提供氨基喹唑啉化合物，其盐和用途。 化合物具有式（I）或立体异构体，几何异构体，互变异构体，N-氧化物，水合物，溶剂合物，代谢物，药学上可接受的盐或前药。 本文还提供含有本文公开的化合物的药物组合物，以及化合物或组合物用于预防，控制，治疗或减轻患者中增殖性疾病的严重性并调节蛋白酪氨酸激酶活性的用途。